Delving into the Latest Updates on Respiratory Syncytial Virus Vaccine (GSK) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms

Respiratory Syncytial Virus Vaccine, Adjuvanted, RSV vaccine, RSV_PreF3 Vaccine

+ [12]

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

Respiratory Syncytial Virus InfectionsCOVID-19Herpes Zoster+ [1]

Inactive Indication-

Originator Organization

GSK Plc

Active Organization

GSK PlcGlaxoSmithKline Biologicals SAGlaxoSmithKline Australia Pty Ltd.

+ [2]

Inactive Organization-

License Organization

Yikang Biological (Suzhou Co Ltd.

Chongqing Zhifei Biological Products Co., Ltd.

GSK Plc

+ [1]

Drug Highest PhaseApproved

First Approval Date

United States (03 May 2023),

Respiratory Syncytial Virus Infections

RegulationPriority Review (United States)

Login to view timeline

A Phase 3 randomized, placebo-controlled observer blindstudy in India to evaluate immune responsereactogenicity and safety of a single intramusculardose of RSVPreF3 OA investigational vaccine whenadministered to older adults =60 years of age andadults 50-59 years of age at increased risk ofrespiratory syncytial virus lower respiratory tractdisease. - NIL

Start Date01 Oct 2024

Sponsor / Collaborator

GlaxoSmithKline Biologicals SA

NCT06593210

/ RecruitingPhase 3IIT

Safety and Immunogenicity of Non-live, Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine in Allogeneic Stem Cell Transplant and Lung Transplant Recipients

Adjuvant, non-live RSV vaccine will be administered to adult lung and allogeneic hematopoietic stem cell transplant recipients. The safety and immunogenicity of this intervention will be studied. Blood work will be collected before and after the intervention, to assess humoral and cellular immunity. Participants will be followed for adverse reaction, hospitalization, RSV breakthrough infection, graft rejection or graft versus host disease. This study has Health Canada and UHN REB approval.

Start Date01 Oct 2024

Sponsor / Collaborator

University Health Network

[+1]

NCT06614725

/ RecruitingPhase 3

A Phase 3, Randomized, Placebo-controlled, Observer-blind Study in India to Evaluate Immune Response, Reactogenicity and Safety of a Single Intramuscular Dose of RSVPreF3 OA Investigational Vaccine When Administered to Older Adults >=60 Years of Age and Adults 50-59 Years of Age at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease

The purpose of the study is to evaluate the immunogenicity and safety of a single dose of investigational RSVPreF3 OA vaccine in Indian older adults 60 years of age (YOA) and above and Indian adults 50-59 YOA at increased risk of RSV-LRTD.

Start Date01 Oct 2024

Sponsor / Collaborator

GSK Plc

100 Clinical Results associated with Respiratory Syncytial Virus Vaccine (GSK)

Login to view more data

100 Translational Medicine associated with Respiratory Syncytial Virus Vaccine (GSK)

Login to view more data

100 Patents (Medical) associated with Respiratory Syncytial Virus Vaccine (GSK)

Login to view more data

66

Literatures (Medical) associated with Respiratory Syncytial Virus Vaccine (GSK)

01 Jul 2025·DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Development and evaluation of ELISA serological immunoassays for influenza and respiratory syncytial viruses

Article

Author: Portet-Sulla, Vincent ; Rameix-Welti, Marie-Anne ; Bizot, Etienne ; Vauloup-Fellous, Christelle ; Eleouet, Jean-François ; Warnakulasuriya, Fairly ; Soutiere, Marie-Pierre ; Claudet, Alexandra ; Lebigot, Elise ; Bouhelal, Hana-Sofia ; Alcover, Noémi ; Galloux, Marie

INTRODUCTION:

Respiratory syncytial virus (RSV) and influenza are major causes of respiratory infections globally. Although vaccines are available, serological tools to assess population-level immunity and maternal antibody transfer remain limited. This study aimed to develop and evaluate ELISA assays for detecting anti-RSV and anti-influenza antibodies as a basis for future maternal-fetal immunity research.

MATERIALS AND METHODS:

In this study, we designed ELISA immunoassays using various influenza and RSV antigens. Sensitivity and specificity were calculated using sera from presumed seronegative infants and seropositive adults.

RESULTS:

The influenza vaccine-based ELISA achieved 98.3 % sensitivity and 100 % specificity. The pre-fusion F protein of RSV (Arexvy®) showed 97.5 % sensitivity and 97.4 % specificity. Other antigen combinations performed less optimally.

DISCUSSION:

These ELISA assays are scalable tools for seroepidemiological and maternal transfer studies. Future work will include correlation with neutralizing antibodies and paired maternal-infant analyses.

01 Jun 2025·Lancet Respiratory Medicine

Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial

Article

BACKGROUND:

Duration of protection after respiratory syncytial virus (RSV) vaccination is unknown. This study aimed to evaluate efficacy and safety over three RSV seasons of the AS01_E-adjuvanted RSV prefusion F protein-based vaccine (RSVPreF3 OA) against RSV-related lower respiratory tract disease (RSV-LRTD) in older adults.

METHODS:

In this randomised, observer-blind, placebo-controlled, phase 3 trial (AReSVi-006), participants aged 60 years or older in 275 centres (ie, GP practices and clinical research sites) across 17 countries in Africa, Asia, Oceania, Europe, and North America were randomly assigned (1:1) to receive RSVPreF3 OA or placebo before RSV season one. RSVPreF3 OA recipients were re-randomly assigned (1:1) before RSV season two to receive a second RSVPreF3 OA dose (RSV revaccination group) or placebo (RSV single-dose group). Recipients of placebo before RSV season one also received placebo before season two (placebo group). The primary objective (efficacy against first occurrence of RSV-LRTD over one RSV season) was reported previously. Confirmatory secondary objectives were to demonstrate efficacy over three RSV seasons of a single RSVPreF3 OA dose and of a first dose followed by revaccination 1 year later, against RSV-LRTD, overall and by RSV subtype (success criteria: lower limits of two-sided CIs around efficacy estimates >20% [RSV-LRTD] and >0% [RSV-LRTD by RSV subtype]). This study is registered with ClinicalTrials.gov, NCT04886596, and is complete.

FINDINGS:

Participants were enrolled between May 25, 2021, and Jan 31, 2022. Efficacy analyses included 12 468 RSVPreF3 OA recipients and 12 498 placebo recipients. Cumulative efficacy over three seasons of one RSVPreF3 OA dose was 62·9% (97·5% CI 46·7-74·8) against RSV-LRTD, 69·8% (42·2-85·7) against RSV A-related LRTD, and 58·6% (35·9-74·1) against RSV B-related LRTD (median follow-up from day 15 post-dose one 30·6 months [IQR 26·2-32·0]). Efficacy was observed over three seasons among participants aged 60-69 years, participants aged 70-79 years, pre-frail participants (ie, those with a walking speed of 0·4-0·99 m/s in a gait speed test), and participants with pre-existing conditions that increase the RSV-LRTD risk. Efficacy against RSV-LRTD decreased over time. A first RSVPreF3 OA dose followed by revaccination 1 year later had an efficacy that was within the same range as that of one dose. RSVPreF3 OA showed a clinically acceptable safety profile. Between dose one and trial end, eight (<1%) participants in the RSV single-dose group, 12 (<1%) in the RSV revaccination group, and 12 (<1%) in the placebo group had a serious adverse event considered to be related to the trial intervention by the investigator. Five deaths were assessed as related to the trial intervention by the investigator: three in the vaccine groups (cardiopulmonary failure, cardiac arrest, and left ventricular failure) and two in the placebo group (death of unknown cause and pulmonary embolism).

INTERPRETATION:

A single RSVPreF3 OA dose was efficacious against RSV-LRTD over three RSV seasons in people aged 60 years or older, despite a decrease in efficacy over time. Further research is needed to establish the optimal revaccination strategy. These results support the favourable benefit-risk profile of RSVPreF3 OA to help protect against RSV-LRTD for at least three RSV seasons.

FUNDING:

GSK.

01 May 2025·MEDICAL SCIENCE MONITOR

Editorial: Surveillance of Seasonal Respiratory Syncytial Virus (RSV) Infection in Children and Vulnerable Adults Drives Vaccine Development and New Immunization Programs.

Author: Parums, Dinah V

Respiratory syncytial virus (RSV) infection remains a significant global health problem, particularly affecting infants <5 years of age who are susceptible to severe RSV disease. New approaches to protecting infants include recommendations for maternal immunization. There are currently three available RSV vaccines that include an AS01E-adjuvanted RSV prefusion F vaccine (Arexvy), a non-adjuvanted bivalent RSV prefusion F vaccine (Abrysvo), and an mRNA vaccine (MResvia). Seasonal use of Abrysvo is recommended for women between 32-36 weeks of pregnancy. The long-acting monoclonal antibody, nirsevimab (Beyfortus), targets the surface F protein of RSV and is effective in late preterm and term infants. The adjuvanted RSV vaccine, Arexvy, is the first approved vaccine to prevent RSV lower respiratory tract infection in adults ≥60 years. Recent modeling and clinical studies have begun to address some of the concerns regarding the safety and efficacy of new RSV vaccines in children, pregnant women, and the elderly. This editorial aims to describe how global surveillance of increasing seasonal RSV respiratory tract infections has driven the development of new vaccines and immunization programs for infants, children, pregnant women, and vulnerable adults.

278

News (Medical) associated with Respiratory Syncytial Virus Vaccine (GSK)

17 Jun 2025

·www.prnewswire.com

Clover Initiates Phase I Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates

-- Potential First-in-Class Respiratory Combination Vaccine Candidates SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) Enter the Clinical Trial Stage -- SHANGHAI, June 17, 2025 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced that enrollment of the first participants has been completed in a Phase I clinical trial evaluating SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3) respiratory combination vaccine candidates based on prefusion-stabilized F (PreF)-Trimer subunit vaccine antigens utilizing Clover's Trimer-Tag vaccine technology platform. "We are pleased to announce the Phase I clinical trial initiation of our potential first-in-class combination vaccine candidates SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3), further demonstrating the differentiated value of our validated Trimer-Tag platform," said Joshua Liang, Chief Executive Officer & Board Director of Clover. "While currently approved protein-based RSV vaccines are safe & effective, critical gaps persist globally, including the inability to prevent significant respiratory disease burden caused by other viruses related to RSV such as human metapneumovirus (hMPV) and parainfluenza virus type 3 (PIV3). Thus, we look forward to the clinical trial results for our respiratory combination vaccine candidates in order to maximize our impact on public health globally." In October 2024, Clover announced Phase I results in 70 older adults (60-85 years) for Clover's non-adjuvanted RSV PreF vaccine candidate (SCB-1019) compared head-to-head to GSK's AS01E-adjuvanted RSV vaccine (AREXVY), and results indicated a potential best-in-class combined immunogenicity & tolerability profile of SCB-1019. These results supported the further development and evaluation of SCB-1019 in combination with the PreF-Trimer antigens for hMPV and PIV3, which are also utilizing the Trimer-Tag platform. The ongoing Phase I trial for Clover's combination vaccine candidates is enrolling up to 192 older adults (60-85 years), and the participants will be randomized to receive either SCB-1022 (RSV+hMPV), SCB-1033 (RSV+hMPV+PIV3) or SCB-1019 (RSV) comparator. The study will assess safety, reactogenicity and immunogenicity. About Clover Clover Biopharmaceuticals is a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world. With integrated research and development, manufacturing and commercial capabilities as well as strong partnerships with organizations globally, Clover has a diverse pipeline of candidates that have the potential to meaningfully reduce the burden of vaccine-preventable diseases—and to make more diseases preventable.  Clover Forward-looking Statements This press release contains certain forward-looking statements and information relating to us and our subsidiaries that are based on the beliefs of our management as well as assumptions made by and information currently available to our management. When used, the words "aim," "anticipate," "believe," "could," "estimate," "expect," "going forward," "intend," "may," "might," "ought to," "plan," "potential," "predict," "project," "seek," "should," "will," "would" and the negative of these words and other similar expressions, as they relate to us or our management, are intended to identify forward-looking statements. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. We give no assurance that these expectations and assumptions will prove to have been correct. Because forward-looking statements relate to the future, they are participant to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. We caution you therefore against placing undue reliance on any of these forward-looking statements. Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time. SOURCE Clover Biopharma WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 1VaccineClinical Result

13 Jun 2025

·pharma.economictimes.indiatimes.com

GSK applies to EU regulator for expanded use of RSV vaccine

Bengaluru: GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults below the age of 50 who are at risk of the disease, the British drugmaker said on Friday. If approved in the European Union, the vaccine, Arexvy , would compete in the 18-49 age group with Pfizer 's Abrysvo. Arexvy is currently only approved in the EU for adults aged 60 and above, and for preventing RSV-related disease in at-risk adults aged 50 to 59. RSV is a common respiratory virus that causes seasonal infections such as the flu and is a leading cause of pneumonia and death in infants and older adults. While GSK's vaccine was the first RSV vaccine to be approved by European and U.S. authorities in 2023 for older adults, it has since lagged behind rivals and sales have fallen sharply. In the first quarter, Arexvy generated revenue of just 78 million pounds ($105.72 million), down 57% from a year earlier. GSK had expected Arexvy to be a blockbuster product, estimating peak annual sales of 3 billion pounds, but sales have missed market expectations for several quarters. An expanded approval could help GSK better compete with Pfizer's Abrysvo and Moderna's mRESVIA vaccine, and revive sales. On Thursday, U.S. regulators approved use of mRESVIA in adults aged 18 to 59 years at increased risk of disease. The EU's health regulator is expected to decide in the first half of 2026 on the expanded use of Arexvy, GSK said, adding that it was working on making similar applications to U.S. and Japanese regulators as well. In January, the U.S. Food and Drug Administration announced that GSK and Pfizer's RSV vaccines will carry warnings that the vaccines can increase the risk of developing Guillain-Barre syndrome, a rare neurological disorder. ($1 = 0.7378 pounds) (Reporting by Pushkala Aripaka in Bengaluru; Editing by Rashmi Aich and Susan Fenton)

Drug ApprovalVaccine

13 Jun 2025

·pipelinereview.com

GSK’s RSV vaccine, Arexvy, accepted for regulatory review by the European Medicines Agency to expand use in adults 18 years and older

LONDON, UK I June 13, 2025 I GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency (EMA) has accepted the company’s regulatory application to expand the use of its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine to include adults from 18 years of age. Arexvy was the first RSV vaccine approved in the European Economic Area for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults aged 60 and older, and for those aged 50-59 years who are at increased risk for RSV disease. RSV is a common contagious virus affecting the lungs and breathing passages and impacts an estimated 64 million people of all ages globally every year. 1 RSV can exacerbate certain medical conditions, and lead to severe illness resulting in hospitalisation and even death. 2,3,4 A European regulatory decision on this submission is anticipated in H1 2026. GSK is continuing to seek expanded indications for its RSV vaccine in other geographies including the US and Japan. About GSK’s RSV vaccine Respiratory Syncytial Virus Vaccine, Adjuvanted, contains recombinant RSV glycoprotein F stabilised in the prefusion conformation (RSVPreF3). This antigen is combined with GSK’s proprietary AS01 E adjuvant. The use of this vaccine should be in accordance with official recommendations. As with any vaccine, a protective immune response may not be elicited in all vaccinees. The vaccine has been approved for the prevention of RSV-LRTD in individuals 60 years of age and older in more than 60 countries. In addition, it is approved for use in individuals aged 50-59 who are at increased risk due to certain underlying medical conditions in more than 50 markets, including the US, Japan and Europe. Please refer to the updated Product Information (PI) for important dosage, administration, and safety information in Europe at this link: http://www.ema.europa.eu/medicines/human//EPAR/arexvy The GSK proprietary AS01 adjuvant system contains STIMULON QS-21 adjuvant licensed from Antigenics Inc, a wholly owned subsidiary of Agenus Inc. STIMULON is a trademark of SaponiQx Inc., a subsidiary of Agenus. About RSV in adults RSV is a common contagious virus affecting the lungs and breathing passages, and impacts an estimated 64 million people of all ages globally every year. 1 Adults can be at increased risk for RSV disease due to certain comorbidities, immune compromised status, or advanced age. 4 RSV can exacerbate conditions, including COPD, asthma, and chronic heart failure and can lead to severe outcomes, such as pneumonia, hospitalisation, and death. 4 About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com. Notes: The European Medicines Agency reviews medicines for European Union member states, as well as in the European Economic Area (EEA) countries Iceland, Norway and Liechtenstein. References SOURCE: GlaxoSmithKline

Drug ApprovalVaccine

100 Deals associated with Respiratory Syncytial Virus Vaccine (GSK)

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Respiratory Syncytial Virus Infections	United States	GlaxoSmithKline Biologicals SA	03 May 2023

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Phase 3	United States	GSK Plc	29 Apr 2024
COVID-19	Phase 3	Belgium	GSK Plc	29 Apr 2024
COVID-19	Phase 3	Netherlands	GSK Plc	29 Apr 2024
COVID-19	Phase 3	Spain	GSK Plc	29 Apr 2024
Herpes Zoster	Phase 3	United States	GSK Plc	28 Jul 2023
Herpes Zoster	Phase 3	Canada	GSK Plc	28 Jul 2023
Influenza, Human	Phase 3	New Zealand	GSK Plc	27 Apr 2021
Influenza, Human	Phase 3	Panama	GSK Plc	27 Apr 2021
Influenza, Human	Phase 3	South Africa	GSK Plc	27 Apr 2021

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05879107 (CTgov)	Phase 3	Respiratory Syncytial Virus Infections	1,113	PCV20+RSVPreF3 OA investigational vaccine (Co-administration Group)	wlwzinhyir(jsvenpcguh) = ehntrkoafs swieszlyoi (lndfpgwzzf, nwnawwbcta - xqiqbfnupn) View more	-	18 May 2025
				PCV20+RSVPreF3 OA investigational vaccine (Control Group)	wlwzinhyir(jsvenpcguh) = wlvsrswljo swieszlyoi (lndfpgwzzf, pfsuwoivlq - trumkvigxt) View more
NCT04886596 (AReSVi-006, Pubmed) Manual	Phase 3	Respiratory Syncytial Virus Infections	24,966	RSVPreF3 OA	ncmnygkivb(wjuithrklz) = zwuzyeybpy iqwjkqjzhb (vvdcztenrv, 46.7 - 74.8) View more	Positive	11 Apr 2025
				Placebo	egidzytfaj(kfthgsnahq) = ocaudxpuok rrywyeaode (wljcoghjtq )
NCT05966090 (RSV-OA=ADJ-020, CTgov)	Phase 3	Herpes Zoster \| Respiratory Syncytial Virus Infections	530	HZ/su vaccine+RSVPreF3 OA investigational vaccine (Co-administration Group)	jkaxfdahon(pbdxrifyfr) = zieivgbphl kuvmooxnqv (ysdafneopt, tisbippuet - yncxckbaub) View more	-	01 Apr 2025
				HZ/su vaccine+RSVPreF3 OA investigational vaccine (Control Group)	jkaxfdahon(pbdxrifyfr) = fmcfxbouvm kuvmooxnqv (ysdafneopt, edrrydsntb - gurwzbsdyd) View more
NCT04886596 (AReSVi-006, Company_Website) Manual	Phase 3	Respiratory Syncytial Virus Infections	-	Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted)	mxfcexsuen(sqfgyubsvi) = umrlkigqsx gfziwosamv (jibwthvjul ) View more	Positive	08 Oct 2024
				Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) (Season one)	mxfcexsuen(sqfgyubsvi) = cohjfppkdg gfziwosamv (jibwthvjul ) View more
NCT05590403 (CTgov)	Phase 3	Respiratory Syncytial Virus Infections	1,544	RSVPreF3 OA investigational vaccine (Adults HA-RSV Group)	dgombfqysn(xvrvghrlcs) = idgvxdmytw dmkmwhrryl (fcatvyzsuq, vemqycqnzp - naxtbdjigh) View more	-	21 May 2024
				RSVPreF3 OA investigational vaccine (OA-RSV Group)	dgombfqysn(xvrvghrlcs) = bymvhzazfo dmkmwhrryl (fcatvyzsuq, kjzlwsgepn - vqyihkbxsw) View more
NCT05559476 (CTgov)	Phase 3	Respiratory Syncytial Virus Infections \| Influenza, Human	1,029	FLU HD vaccine+RSVPreF3 OA investigational vaccine (Co-Ad Group)	oauubokvbi(didkzdncct) = mxttnmlbdk dorbxhwkyn (kwypqfnbbd, xlljfhadxb - knqgwwzgda) View more	-	04 Apr 2024
				FLU HD vaccine+RSVPreF3 OA investigational vaccine (Control Group)	oauubokvbi(didkzdncct) = tadpxintlx dorbxhwkyn (kwypqfnbbd, neadicohgj - nyncniihox) View more
NCT05568797 (CTgov)	Phase 3	Respiratory Syncytial Virus Infections \| Influenza, Human	1,045	FLU vaccine+RSVPreF3 OA vaccine (Co-Ad Group)	vwdhahnyhg(odqacoqobm) = bnzjnvhbqo infrenlqer (tfgjcgowey, htevphekkp - ftibyexzzp) View more	-	15 Mar 2024
				FLU vaccine+RSVPreF3 OA vaccine (Control Group)	vwdhahnyhg(odqacoqobm) = rbhduiehns infrenlqer (tfgjcgowey, xpgvdzckew - eqnsswndmo) View more
NCT04886596 (Pubmed) Manual	Phase 3	Respiratory Syncytial Virus Infections	24,966	RSVPreF3 OA vaccineal Virus Prefusion F Protein Vaccine (RSVPreF3 OA)	uybuksnppt(sgayxmagvi) = fjsmjjjzfs ssdrxcyudx (kyjrwqtwtl ) View more	Positive	25 Jan 2024
				RSVPreF3 OA vaccine (≥1 cardiorespiratory)	uybuksnppt(sgayxmagvi) = immmzlqpra ssdrxcyudx (kyjrwqtwtl ) View more
NCT04732871 (Phase 3 Trial, CTgov)	Phase 3	Respiratory Syncytial Virus Infections	1,720	RSVPreF3 OA investigational (RSV_annual)	ypowfwtajq(golvyrjuap) = kobfuemlzj dwyxnbeobh (nxaelvdttf, jujmsvqgsa - bihdmiruui) View more	-	21 Dec 2023
				RSVPreF3 OA (RSV_flexible Revaccination)	ypowfwtajq(golvyrjuap) = kjoksmepne dwyxnbeobh (nxaelvdttf, xxshlklgrj - qsgtiwzusg) View more
NCT05590403 (Biospace) Manual	Phase 3	Respiratory Syncytial Virus Infections	1,520	AREXVY	osddtpzcvc(onrxfvstmk) = non-inferior immune responses observed in adults aged 50-59 compared to adults aged 60 and older iagfrsltfc (zkjqurlaaa ) Met View more	Positive	25 Oct 2023